{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemzar&page=32", "query": { "intervention": "Gemzar", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 1628, "total_pages": 163, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemzar&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gemzar&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T22:58:32.132Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01057264", "title": "HAI Abraxane With Gemcitabine and Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "HAI Abraxane", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2010-01", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-11-14T22:58:32.132Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01057264" }, { "nct_id": "NCT00887809", "title": "Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma", "Leiomyosarcoma", "Malignant Fibrous", "Histiocytoma", "Angiosarcoma" ], "interventions": [ { "name": "gemcitabine", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 47, "start_date": "2009-04", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-01-25", "last_synced_at": "2026-11-14T22:58:32.132Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887809" }, { "nct_id": "NCT05655949", "title": "Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bile Duct Cancer", "Cholangiocarcinoma", "Cholangiocarcinoma Non-resectable", "Cholangiocarcinoma Metastatic", "Metastatic Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Yttrium-90", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-13", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-11-14T22:58:32.132Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05655949" }, { "nct_id": "NCT00004093", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Navelbine", "type": "DRUG" }, { "name": "Taxol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "1999-08", "completion_date": "2002-03", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-11-14T22:58:32.132Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004093" }, { "nct_id": "NCT02448537", "title": "A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Sarcoma" ], "interventions": [ { "name": "PM01183", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2015-08", "completion_date": "2019-04-01", "has_results": true, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-11-14T22:58:32.132Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02448537" }, { "nct_id": "NCT03558087", "title": "Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew Galsky", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2018-07-13", "completion_date": "2024-03-07", "has_results": true, "last_update_posted_date": "2024-06-27", "last_synced_at": "2026-11-14T22:58:32.132Z", "location_count": 7, "location_summary": "Duarte, California • Los Angeles, California • New York, New York + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03558087" }, { "nct_id": "NCT00438204", "title": "Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2006-05", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-11-14T22:58:32.132Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • Detroit, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00438204" }, { "nct_id": "NCT02722538", "title": "Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Cancer" ], "interventions": [ { "name": "Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taris Biomedical LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2016-05-31", "completion_date": "2019-05-02", "has_results": false, "last_update_posted_date": "2023-09-18", "last_synced_at": "2026-11-14T22:58:32.132Z", "location_count": 5, "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02722538" }, { "nct_id": "NCT02632448", "title": "A Study of LY2880070 in Participants With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Colorectal Cancer", "Breast Cancer", "Ovarian Cancer", "Colon Cancer", "Rectal Cancer", "Neoplasms", "Endometrial Cancer", "Soft Tissue Sarcoma", "Triple Negative Breast Cancer", "Pancreas Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "LY2880070", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Esperas Pharma Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2016-05-16", "completion_date": "2025-04-14", "has_results": false, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-11-14T22:58:32.132Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Detroit, Michigan", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632448" }, { "nct_id": "NCT02542293", "title": "Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Carcinoma NSCLC" ], "interventions": [ { "name": "Durvalumab +Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel + carboplatin", "type": "DRUG" }, { "name": "Gemcitabine + cisplatin", "type": "DRUG" }, { "name": "Gemcitabine + carboplatin", "type": "DRUG" }, { "name": "Pemetrexed + cisplatin", "type": "DRUG" }, { "name": "Pemetrexed + carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 953, "start_date": "2015-11-03", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-14T22:58:32.132Z", "location_count": 15, "location_summary": "Anaheim, California • San Diego, California • Santa Rosa, California + 12 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Florham Park", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02542293" } ] }